Associate Professor Abraham Schneider, DDS, PhD
Research conducted in the Schneider laboratory focuses on gaining a better understanding on the role of antidiabetic biguanides as potential therapeutic agents in (a) oral cancer and (b) mesenchymal stem cell (MSC)-based skeletal regeneration. Specifically, we are investigating the role of organic cation transporters (OCTs) belonging to the SLC22A gene family on the cellular uptake and potential antineoplastic action of the first-line, highly hydrophilic antidiabetic drug metformin and the related biguanide phenformin in oral squamous cell carcinoma. Likewise, we are interested in elucidating the potential anabolic action of metformin in the skeleton since recent evidence has demonstrated that metformin is capable of inducing bone marrow MSC differentiation into functional osteoblasts. To this end metformin, a relatively inexpensive drug with minimal toxicities following long-term use could be repurposed as a pharmacological enhancer of bone regeneration. In this regard, the Schneider lab is investigating whether OCT expression and function in alternative sources of human MSCs such as those derived from induced pluripotent stem cells and the umbilical cord Wharton’s jelly may serve as potential biomarker to predict positive osteogenic responses to metformin in mesenchymal stem cell-based bone regeneration.
Wang P, Ma T, Guo D, Hu K, Shu Y, Xu HHK, A Schneider. Metformin Induces Osteoblastic Differentiation of Human Induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells. J Tissue Eng Regen Med 2017; 1-10. https://doi.org/10.1002/term.2470.
Wisniewski DJ, T Ma and A Schneider. Advances in the chemopreventive targeting of oral carcinogenesis. Current Oral Health Reports 2(2): 63-72, 2015.
Schneider A. Mouse Models to Study Metformin Effects in Carcinogenesis. In: Berger NA (ed) Murine Models, Energy Balance and Cancer. Energy Balance and Cancer 10: 271-292, 2015. Springer International Publishing, Switzerland.
Patel H, RH Younis, RA Ord, JR Basile and A Schneider. Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin. J Oral Pathol Med 42(3):250-6, 2013.
Vitale-Cross L, AA Molinolo, D Martin, RH Younis, M Takashi, V Patel, W Chen, A Schneider and JS Gutkind. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 5(4): 562-73, 2012.
Schneider A and RB Gartenhaus. AMPK signaling: A targetable tumor suppressor pathway? Cancer Biology and Therapy 10(11): 1178-1181, 2010.
Wang X, A Schneider. HIF2α-mediated activation of the Epidermal Growth Factor Receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31(7):1202-10, 2010.
Schneider A, RH Younis and JS Gutkind. Hypoxia-Induced Energy Stress Inhibits the mTOR Pathway by Activating an AMPK/REDD1 Signaling Axis in Head and Neck Squamous Cell Carcinoma. Neoplasia 10(11): 1295-1302, 2008.
Schneider A, LM Kalikin, AC Mattos, ET Keller, MJ Allen, KJ Pienta and LK McCauley. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146 (4): 1727-1736, 2005.
Schneider A, JM Taboas, LK McCauley and PH Krebsbach. Skeletal homeostasis in tissue-engineered bone. J Orthop Res 21(5): 859-864, 2003.
EDUCATION AND TRAINING:
Dental Degree: DDS, Peruvian University Cayetano Heredia
Residency: Periodontics, University of Connecticut Health Center
Doctoral Degree: Oral Health Sciences, University of Michigan